Samsung Biologics said Tuesday that the company has signed five contract manufacturing deals to bring the total value of its annual orders this year to an all-time high of 3.48 trillion won ($2.7 billion). According to Samsung Biologics’ regulatory filing, the company has recently inked one new and four expanded deals with a pharmaceutical company based in Asia. The five contracts are worth a total of around 76.
Samsung Biologics engages suppliers to advance global decarbonization targets tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Samsung Biologics has surpassed 3 trillion won ($2.3 billion) in accumulated annual orders with its contract development and manufacturing organization (CDMO) drug manufacturing business thanks to a recent large-scale contract with an Asia-based pharmaceutical company, according to the drugmaker, Tuesday.